Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PVLA Palvella Therapeutics

休市中 02-06 16:00:00 EST

82.20

+5.77

+7.55%

盘后82.20

+0.000.00%

19:45 EST

最高85.05	最低78.93	成交量39.64万
今开78.93	昨收76.43	日振幅8.00%
总市值9.73亿	流通市值5.88亿	总股本1,184万
成交额3,260万	换手率5.54%	流通股本715.85万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":82.2,"timestamp":1770411600000,"preClose":76.43,"halted":0,"volume":396365,"hourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":82.2,"latestTime":"19:45 EST","volume":1317,"amount":108279.34,"timestamp":1770425107894,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07549391600157,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"休市中","change":5.77,"latestTime":"02-06 16:00:00 EST","open":78.93,"high":85.045,"low":78.93,"amount":32604584.571349997,"amplitude":0.080008,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":76.43,"preHourTrading":{"tag":"盘前","latestPrice":78.49,"preClose":76.43,"latestTime":"08:46 EST","volume":2,"amount":156.98999,"timestamp":1770385565702,"change":2.06,"changeRate":0.026953,"amplitude":0.000131},"postHourTrading":{"tag":"盘后","latestPrice":82.2,"preClose":82.2,"latestTime":"19:45 EST","volume":1317,"amount":108279.34,"timestamp":1770425107894,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0324672411608795,"optionData":{"bulkOrders":[{"symbol":"PVLA","call":true,"expireDate":1771563600000,"strike":"110.0","timestamp":1770389734166,"price":0.8,"volume":1500,"amount":120000,"type":"-"}]},"impliedVol":1.8307,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/PVLA","defaultTab":"news","newsList":[{"id":"1134522020","title":"Palvella Therapeutics发布公司进展与2026年展望：推进后期临床阶段管线，以平台化策略攻克无FDA批准疗法的严重罕见皮肤病及血管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1134522020","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134522020?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:30","pubTimestamp":1767961814,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics近期披露了公司最新动态及面向2026年的战略规划。该公司正全力推进其处于后期临床阶段的产品管线与技术平台，致力于解决目前尚无美国食品药品监督管理局（FDA）批准疗法的多种严重罕见皮肤病及血管畸形疾病。这一举措凸显了公司聚焦未满足临床需求的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1132581978","title":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=1132581978","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132581978?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:30","pubTimestamp":1765888255,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1123205248","title":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123205248","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123205248?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:01","pubTimestamp":1765796473,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病，目前尚无FDA批准的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1134453895","title":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=1134453895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134453895?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:28","pubTimestamp":1763573311,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1121184983","title":"Palvella Therapeutics发布2025年第三季度财务业绩并提供公司更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121184983?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:24","pubTimestamp":1763573099,"startTime":"0","endTime":"0","summary":"11月11日 - Palvella Therapeutics Inc 发表声明：*PALVELLA THERAPEUTICS发布2025年第三季度财务业绩并提供公司更新*PALVELLA THERAPEUTICS INC：第三季度每股收益为-$1.03","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1156492120","title":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156492120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156492120?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:12","pubTimestamp":1763554332,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1160931524","title":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1160931524","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160931524?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:01","pubTimestamp":1762340484,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1177709996","title":"Palvella Therapeutics宣布拓展Qtorin™雷帕霉素的开发范围，用于治疗临床意义重大的血管角化瘤——一种罕见的慢性致残性淋巴疾病，目前尚无FDA批准的疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1177709996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177709996?lang=zh_cn&edition=full","pubTime":"2025-09-24 18:02","pubTimestamp":1758708121,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布拓展Qtorin™雷帕霉素的开发范围，用于治疗临床意义重大的血管角化瘤——一种罕见的慢性致残性淋巴疾病，目前尚无FDA批准的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1107503642","title":"Palvella Therapeutics完成Qtorin™雷帕霉素治疗皮肤静脉畸形的2期Toiva试验患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1107503642","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107503642?lang=zh_cn&edition=full","pubTime":"2025-09-15 19:30","pubTimestamp":1757935818,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics已完成其Qtorin™雷帕霉素用于治疗皮肤静脉畸形的2期Toiva临床试验的患者招募工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1102713602","title":"Palvella Therapeutics任命资深科学家兼生物制药高管David W. Osborne博士为首席创新官，进一步充实领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1102713602","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102713602?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:30","pubTimestamp":1756899025,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布任命经验丰富的科学家兼生物制药行业高管David W. Osborne博士担任首席创新官，以此举措进一步加强公司领导层实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139","PVLA"],"gpt_icon":0},{"id":"2509407655","title":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509407655","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509407655?lang=zh_cn&edition=full","pubTime":"2025-02-05 20:11","pubTimestamp":1738757515,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics(PVLA.US)获TD Cowen首次覆盖，给予买入评级, 目标价44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05201147968471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PVLA","LENZ","TD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":0.0718},{"period":"1month","weight":-0.1864},{"period":"3month","weight":0.0561},{"period":"6month","weight":1.0098},{"period":"1year","weight":4.48},{"period":"ytd","weight":-0.2147}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Palvella Therapeutics, Inc.在内华达的法律下成立于2013年5月24日。该公司是一家生物技术公司，历史上发现并开发了基于Anticalin蛋白的药物，以独特和变革性的方式靶向已验证的疾病途径。2024年3月27日，公司实施了措施，以最大限度地提高其从其合作候选药物临床管道收集潜在里程碑的能力，并保持其考虑其他战略选择的能力。该公司的临床管线包括与合作者合作的免疫肿瘤学或IO双特异性药物，包括靶向PD-L1和4-1BB的S095012（也称PRS-344）、靶向CD228和4-1BB的SGN-BB228（也称PRS-346）以及靶向GPC3和4-1BB的BOS-342（也称PRS-342）。Anticalin蛋白是公司专有的，是一类新型疗法，已在临床上通过与领先制药公司的合作关系得到验证。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.026341},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.082116},{"month":5,"riseRate":0.5,"avgChangeRate":0.168212},{"month":6,"riseRate":0.4,"avgChangeRate":-0.088952},{"month":7,"riseRate":0.727273,"avgChangeRate":0.169693},{"month":8,"riseRate":0.636364,"avgChangeRate":0.117993},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Palvella Therapeutics(PVLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}